WILMINGTON, Mass. & SAN FRANCISCO / Jul 24, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn’s growing pipeline of early-stage, preclinical therapeutics’ programs. This agreement will grant Autobahn preferred access to Charles River’s industry-standard, state-of-the-art drug discovery and development capabilities. The purpose of the partnership is to accelerate the advancement of novel academic science into transformational new therapies across diverse therapeutic modalities and disease areas.
Under the terms of the agreement, Charles River has made an investment in Autobahn Labs, joining a fundraising round led by Autobahn’s founding investor, Samsara BioCapital. Proceeds from the raise and partnership with Charles River will enable Autobahn to expand the number of partnerships with top-tier academic institutions, advance lead preclinical programs, and identify new opportunities for therapeutics development. In conjunction with the funding, Justin Bryans, Chief Scientific Officer, Discovery for Charles River, has joined Autobahn’s Board of Directors.
“I am looking forward to partnering with the Autobahn Labs team as they develop preclinical therapeutics programs,” said Justin Bryans, Chief Scientific Officer, Discovery, Charles River. “We expect our combined expertise will help progress drug discovery and development programs, ultimately delivering critical therapeutics to patients.”
“We are excited for Charles River to join Samsara BioCapital as an investor and partner in Autobahn’s mission to translate the best of academic biotech,” said Brendan O’Leary, CEO of Autobahn Labs. “Combining Charles River’s industry-leading drug discovery and development capabilities with Autobahn’s deal sourcing and venture creation expertise will allow us to efficiently de-risk academic research with significant therapeutic potential, from novel concept to preclinical drug candidate.”
About Autobahn Labs
Autobahn Labs is a new model for early-stage drug discovery and development, partnering with leading research institutions to accelerate the advancement of novel science to deliver transformational new therapies for patients. Founded in 2019 by Samsara BioCapital, we invest intellectual, financial and physical capital, applying our proven drug discovery framework to efficiently move projects from therapeutic hypothesis to novel drug candidates. For more information, visit www.autobahn-labs.com.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Last Trade: | US$187.98 |
Daily Change: | -3.21 -1.68 |
Daily Volume: | 428,423 |
Market Cap: | US$9.710B |
September 04, 2024 August 07, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB